Adiponectin: Its role in obesity-associated colon and prostate cancers

Santoshi Muppala, Siva K.P. Konduru, Neha Merchant, Judy Ramsoondar, Carlos Karan Rampersad, Balney Rajitha, Vidya Mukund, Jyothsna Kancherla, Anthea Hammond, Tapan Kumar Barik, Mastan Mannarapu, Afroz Alam, Riyaz Basha, Pallaval Veera Bramhachari, Dheeraj Verma, Pinninti Santosh Sushma, Subasini Pattnaik, Ganji Purnachandra Nagaraju

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Adipose tissue synthesizes many proteins and hormones collectively called adipokines, which are linked to a number of diseases, including cancer. Low levels of adiponectin are reported to be a risk factor for obesity-related cancers including colorectal and prostate cancers. Accordingly, obesity/lifestyle-related diseases, including certain cancers, may be treated by developing drugs that act specifically on adiponectin levels in circulation. Adiponectin may also serve as a clinical biomarker in obesity-related diseases. Adiponectin-based therapies are known to inhibit cancer advancement and thus may provide a therapeutic approach to delay cancer progression. Better understanding of the function of adiponectin is of great significance in the fight against cancer. This timely review is concentrated on the role of adiponectin and the impact of obesity on the development of cancers, especially colorectal and prostate cancers.

Original languageEnglish
Pages (from-to)125-133
Number of pages9
JournalCritical Reviews in Oncology/Hematology
StatePublished - 1 Aug 2017


  • Adiponectin
  • Adiponectin receptors
  • Colorectal cancer
  • Obesity
  • Prostate cancer


Dive into the research topics of 'Adiponectin: Its role in obesity-associated colon and prostate cancers'. Together they form a unique fingerprint.

Cite this